4-溴-1-甲基-吡唑-3-甲醛 | 287917-96-8

• 物质功能分类: 有机原料 - 醛类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-溴-1-甲基-吡唑-3-甲醛
• 中文别名: 4-溴-1-甲基-1H-吡唑-3-甲醛；4-溴-1-甲基-1H-吡唑-5-甲醛
• 英文名称: 4-bromo-1-methyl-1H-pyrazole-3-carbaldehyde
• 英文别名: 4-bromo-1-methylpyrazole-3-carbaldehyde
• CAS: 287917-96-8
• 化学式: C₅H₅BrN₂O
• 分子量: 189.011
• InChiKey: KGIYMMPLYIITLL-UHFFFAOYSA-N

物化性质

• 熔点：
  70 °C
• 沸点：
  275.2±20.0 °C(Predicted)
• 密度：
  1.73±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Name:	4-Bromo-1-methyl-1h-pyrazole-3-carbaldehyde 95+% Material Safety Data Sheet
Synonym:
CAS:	287917-96-8

Section 1 - Chemical Product MSDS Name:4-Bromo-1-methyl-1h-pyrazole-3-carbaldehyde 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
287917-96-8	4-Bromo-1-methyl-1H-pyrazole-3-carbald	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 287917-96-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white crystalline solid
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 68 - 71 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H5BrN2O
Molecular Weight: 189

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 287917-96-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Bromo-1-methyl-1H-pyrazole-3-carbaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 287917-96-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 287917-96-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 287917-96-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-1-甲基-吡唑-3-甲醛 在 二乙胺基三氟化硫 作用下， 以 二氯甲烷 为溶剂， 以48.7%的产率得到4-溴-3-二氟甲基-1-甲基吡唑
  参考文献：
  名称：

  Method for the Production of N-Substituted (3-Dihalomethyl-1-Methyl-Pyrazole-4-yl) Carboxamides

  摘要：

  本发明涉及一种制备式(I)的N-取代(3-二卤甲基吡唑-4-基)羧酰胺的方法 其中R1是可选的取代苯基或C3-C7环烷基，R1a是氢或氟，或者R1a与R1一起是可选的取代C3-C5-烷二基或C5-C7-环烷二基，R2是C1-C6-烷基，C2-C6-烯基，C2-C6-炔基或C1-C4-烷氧基-C1-C2-烷基，X是F或Cl，n为0、1、2或3；包括 A)提供式(II)的化合物 其中X是F或Cl，Y是Cl或Br，R2具有上述给定的含义之一 B)将式(II)的化合物与一氧化碳和式(III)的化合物反应 其中R1、R1a和n具有上述给定的含义之一；在钯催化剂的存在下； 用于根据本发明的方法制备的中间体，以及用于它们的制备的方法。

  公开号：

  US20100174094A1
• 作为产物：
  描述：

  4-溴-1,3-二甲基-1H-吡唑 在 manganese(IV) oxide 、 N-溴代丁二酰亚胺(NBS) 、 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 氯苯 为溶剂， 反应 39.0h， 生成 4-溴-1-甲基-吡唑-3-甲醛
  参考文献：
  名称：

  NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF

  摘要：

  由式[1]表示的化合物（在该式中，Z表示N、CH或类似物；X表示NH或类似物；R表示杂环烷基或类似物；R2、R3和R4中的每一个表示氢原子、卤原子、烷氧基或类似物；R5表示杂环烷基或类似物）或其盐。

  公开号：

  US20150322063A1

文献信息

• [EN] PYRIMIDINE PDE10 INHIBITORS<br/>[FR] INHIBITEURS PYRIMIDINES DE PDE10
  申请人：MERCK SHARP & DOHME

  公开号：WO2014081619A1

  公开（公告）日：2014-05-30

  The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及嘧啶化合物，这些化合物用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统障碍的治疗剂。本发明还涉及使用这些化合物来治疗神经和精神障碍，如精神分裂症、精神疾病或亨廷顿病，以及与纹状体功能减退或基底神经节功能障碍相关的疾病。
• Design, synthesis, and biological evaluation of 1,9-diheteroarylnona-1,3,6,8-tetraen-5-ones as a new class of anti-prostate cancer agents
  作者：Xiaojie Zhang、Rubing Wang、German Ruiz Perez、Guanglin Chen、Qiang Zhang、Shilong Zheng、Guangdi Wang、Qiao-Hong Chen

  DOI：10.1016/j.bmc.2016.08.006

  日期：2016.10

  inhibiting prostate cancer cell proliferation. It can be concluded from our data that 1,9-diarylnona-1,3,6,8-tetraen-5-one can serve as a new potential scaffold for the development of anti-prostate cancer agents and that pyridine-4-yls and quinolin-4-yl act as optimal heteroaromatic rings for the enhanced potency of this scaffold. Two of the most potent compounds, 68 and 75, effectively suppress PC-3 cell

  为了寻求更有效的化学疗法来治疗去势抵抗性前列腺癌并受到姜黄素类似物的启发，二十五个（1 E，3 E，6 E，8 E）-1,9-diarylnona-1,3,6,8通过Wittig反应，然后进行Horner-Wadsworth-Emmons反应，已成功合成了带有两个相同末端杂芳族环的-tetraen-5-ones。其中的二十三种是新化合物。WST-1细胞增殖测定法用于评估其对雄激素敏感性和雄激素敏感性人类前列腺癌细胞系的抗增殖作用。与姜黄素相比，二十五个合成化合物中有十八个具有显着改善的效能。最佳化合物78在抑制前列腺癌细胞增殖方面，β-内啡肽的活性比姜黄素高14到23倍。从我们的数据可以得出结论，1,9-二芳基壬娜-1,3,6,8-四烯基5-one可以作为开发抗前列腺癌药物和吡啶-4-基的新的潜在支架。和喹啉-4-基充当最佳杂芳环，以增强该支架的效能。两种最有效的化合物68和75通过激活细胞凋亡和将细胞周期阻滞在G
• [EN] MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS<br/>[FR] DÉRIVÉS D'AZOLOPYRIDINE MACROCYCLIQUES UTILISÉS EN TANT QUE MODULATEURS EED ET PRC2
  申请人：FULCRUM THERAPEUTICS INC

  公开号：WO2020190754A1

  公开（公告）日：2020-09-24

  The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

  本发明涉及用于治疗与Embryonic Ectoderm Development (EED)和/或Polycomb Repressive Complex 2 (PRC2)相关的疾病和障碍的调节剂，是式(I)所示的宏环唑啉衍生物及其组合物，或其药用可接受的盐、前药、溶剂化物、水合物、对映体、异构体或互变异构体，其中X1、X2、X3、A1、A2、Y、R1、R2、R3和R4如本文所述。
• 4-Methylsulfonyl-Substituted Piperidine Urea Compounds
  申请人：MyoKardia, Inc.

  公开号：US20160243100A1

  公开（公告）日：2016-08-25

  The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.

  本发明提供了一种新颖的4-甲基砜取代哌啶脲化合物，可用于治疗扩张型心肌病（DCM）以及与左心室和/或右心室收缩功能障碍或收缩储备相关的疾病。描述了这些化合物的合成和表征，以及治疗DCM和其他形式心脏疾病的方法。
• [EN] SPIROXAZOLIDINONE COMPOUNDS<br/>[FR] COMPOSÉS SPIROXAZOLIDINONE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012024183A1

  公开（公告）日：2012-02-23

  Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety.

  结构式（I）的螺环胺是生长抑素亚型受体5（SSTR5）的选择性拮抗剂，可用于治疗、控制或预防对SSTR5拮抗敏感的疾病，如2型糖尿病、胰岛素抵抗、脂质紊乱、肥胖、动脉粥样硬化、代谢综合征、抑郁症和焦虑症。